Key Takeaways
- Shares of Novo Nordisk and Eli Lilly rose sharply on May 7, 2026, following stronger-than-expected early sales data of their oral weight-loss pills.
- Investors anticipate market expansion as oral GLP-1 drugs attract new patients avoiding injectable treatments, widening obesity treatment access.
- The partnership between drug innovation and patient adoption signals sustained growth despite pricing pressures and competition from biosimilars.
Shares of Danish pharmaceutical leader Novo Nordisk and U.S.-based Eli Lilly climbed significantly on May 7, 2026, after early sales figures suggested their oral weight-loss pills could broaden the obesity treatment market substantially. This partnership between innovative oral GLP-1 therapies and new patient uptake highlights growing optimism that these convenient medications will attract millions currently hesitant to use injectable drugs. The dynamic reflects evolving market forces, including pricing challenges and upcoming biosimilar competition.
Robust Early Sales Indicate Market Growth Potential
In the first quarter, Novo Nordisk reported that sales of its newly released Wegovy oral pill nearly doubled expectations, sparking a sharp increase in its share price. Meanwhile, Eli Lilly, which launched its Foundayo pill months after Novo’s product, recently raised its profit outlook based on strong sales momentum, though their weight-loss treatments remain primarily injectable GLP-1 dominated. Crucially, analysts emphasize that oral formulations appear to be expanding the total patient pool rather than merely shifting users from injectables.
Shams Afzal, managing director at Novo investor Carnegie Investment Counsel, explained that oral pills reduce barriers linked to injection reluctance, encouraging treatment initiation among previously untreated patients. With over 100 million Americans classified as obese but only a small percentage currently prescribed GLP-1 therapies, Novo CEO Mike Doustdar revealed that about 80% of Wegovy users are treatment-naive, underscoring significant untapped patient potential.
Analyst Scenarios and Market Dynamics
Henrik Hallengreen Laustsen, analyst at Jyske Bank, upgraded his market share projections for oral GLP-1 pills from 15–20% to 35–40%, driven by strong demand from self-paying customers and rapid prescriber adoption. A portion of Novo’s surge stemmed from wholesaler stockpiling, but according to BMO Capital’s Evan Seigerman, genuine new patient uptake dominates rather than cannibalization of injectables. Lilly reported over 8,000 doctors had prescribed Foundayo since its U.S. launch in April, with roughly one-third new to oral GLP-1s. Additionally, 45% of Foundayo sales occurred through LillyDirect, a direct-to-consumer platform, while about half of Wegovy volume was self-pay.
Trump’s Tariffs May Spark an AI Gold Rush
While headlines focus on trade wars, our AI has identified one specific $1.5 trillion opportunity that remains completely overlooked. Take the 30-second assessment now to see if your trading profile matches this high-growth play before the opportunity expires.
SEE MY AI ASSESSMENT ➔Pricing pressures remain a notable risk. Novo’s Q1 adjusted U.S. sales declined 11% due to lower realized prices, while Lilly faced similar challenges but mitigated revenue impacts more effectively. Markus Manns, representing Novo and Lilly shareholder Union Investment, pointed to concerns over continued price erosion and imminent biosimilar competition in injectables, emphasizing the need for broader portfolio diversification beyond obesity and diabetes therapies.
Alessandro Valentini, portfolio manager at Novo shareholder Causeway Capital, stressed the positive implications of this partnership between pharmaceutical innovators. He highlighted that prescriptions reflect an expanding patient base, remarking, “It’s not a zero-sum game. It’s an expanding market.”
Partnership: Market Outlook
Citi analysts noted that by mid-April 2026, weekly prescriptions for the Wegovy oral pill reached approximately 207,000, reflecting durable market demand. This growing partnership between novel oral GLP-1 drugs and newly engaged patients suggests continued expansion prospects. Despite challenges from pricing pressures and biosimilar competitors, Novo Nordisk and Eli Lilly appear well positioned to capitalize on an enlarged obesity treatment market, drawing millions who previously avoided injectable options.
